Monitor for definitive contract award from DARPA, which would provide non-dilutive funding and government validation. The stock may see continued momentum on this government endorsement, but the lack of a binding award means the catalyst is incomplete — watch for follow-up 8-K on contract terms.
Price Chart
Executive Summary
NRX Pharmaceuticals' subsidiary NRX Defense Systems received a letter from DARPA indicating its SPARC-TMS clinical trial proposal was selected for negotiation of a potential award. The Phase 2/3 trial combines robotic-enabled TMS with NRX-101 (which has FDA Breakthrough Therapy Designation) for depression remission. This is a non-binding selection — no award has been made and definitive terms remain subject to negotiation, but it represents a significant validation of the company's technology platform by a major government agency.
Key Facts
- NRX Defense Systems (NRXD) received a letter from DARPA selecting its SPARC-TMS proposal for negotiation of a potential award.
- The SPARC-TMS trial is a Phase 2/3 trial combining robotic-enabled Transcranial Magnetic Stimulation with NRX-101 (D-cycloserine/lurasidone) for depression remission.
- NRX-101 previously received FDA Breakthrough Therapy Designation.
- The trial protocol is FDA-approved and posted on clinicaltrials.gov (NCT07227103).
- The study is planned at Harvard McLean Hospital, HOPE Therapeutics clinics, and military treatment facilities including Walter Reed.
- The selection does not constitute a notice of award or commitment by DARPA; final award is subject to successful negotiation of definitive terms.
Financial Impact
No financial terms disclosed. DARPA contract value is TBD and subject to negotiation.
Risk Factors
- No binding award yet — DARPA may not finalize terms or may cancel negotiations.
- NRX Pharmaceuticals is a small-cap biotech with no disclosed revenue from this program; the stock may be volatile on binary government contract news.
- The Phase 2/3 trial carries clinical risk — efficacy or safety issues could derail the program.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-024037 |
| Document: 0001437749-26-024037-index-headers.html | 0001437749-26-024037 |
| Document: 0001437749-26-024037-index.html | 0001437749-26-024037 |
| Document: 0001437749-26-024037.txt | 0001437749-26-024037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.35 $3.16 | ▼ −5.67% | ▼ −8.24% | $2.90 (−13.28%) |
Sep 14, 2026 18d ago | 8-K | $3.49 $3.29 | ▼ −5.73% | ▼ −5.84% | $2.90 (−16.76%) |
Aug 17, 2026 6w ago | 8-K | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 17, 2026 6w ago | Press Release | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 7, 2026 8w ago | 8-K | $3.58 $3.27 | ▼ −8.66% | ▼ −9.06% | $2.90 (−18.85%) |
Jul 22, 2026 10w ago | 8-K | $4.48 $3.23 | ▼ −27.90% | ▼ −25.50% | $2.90 (−35.16%) |
Jun 22, 2026 14w ago | Press Release | $3.90 $3.73 | ▼ −4.36% | ▼ −2.29% | $2.90 (−25.51%) |
Jun 5, 2026 17w ago | Press Release | $4.14 $3.84 | ▼ −7.25% | ▼ −7.82% | $2.90 (−29.83%) |
Jun 4, 2026 17w ago | Press Release | $4.14 $3.84 | ▲ +7.25% | ▲ +7.82% | $2.90 (+29.83%) |
Jun 3, 2026 17w ago | Press Release | $4.05 $3.76 | ▲ +7.16% | ▲ +3.34% | $2.90 (+28.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access